Top

Published in:

01-04-2015

Current status on histological classification in Cushing’s disease

Authors: Luis V. Syro, Fabio Rotondo, Michael D. Cusimano, Antonio Di Ieva, Eva Horvath, Lina M. Restrepo, Min Wong, Donald W. Killinger, Harley Smyth, Kalman Kovacs

Published in: Pituitary | Issue 2/2015

Abstract

Introduction

Managing Cushing’s disease remains a challenge. Surgery is the first option of treatment and it offers a high success rate. Even in cases where biochemical remission is not achieved, it is crucial to obtain surgical tissue for morphological diagnosis because the therapeutic approach can be modified according to the findings.

Materials and Methods

A literature search was performed using PubMed for information regarding pathology and Cushing’s disease.

Results

The histopathological features found in the pituitary gland of patients with Cushing’s disease are presented.

Conclusion

Different subtypes of ACTH-producing pituitary tumors are recognized and characterized. The significance of finding a normal pituitary gland with or without Crooke’s changes is also discussed.

Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50:137–195

Bertagna X, Guignat L (2013) Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 98(4):1307–1318. doi:10.1210/jc.2012-3200 CrossRefPubMed

Gadelha MR, Vieira Neto L (2014) Efficacy of medical treatment in Cushing’s disease: a systematic review. Clin Endocrinol 80(1):1–12. doi:10.1111/cen.12345 CrossRef

Fleseriu M, Petersenn S (2013) New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy. J Neurooncol 114(1):1–11. doi:10.1007/s11060-013-1151-1 CrossRefPubMedCentralPubMed

Feelders RA, Hofland LJ (2013) Medical treatment of Cushing’s disease. J Clin Endocrinol Metab 98(2):425–438. doi:10.1210/jc.2012-3126 CrossRefPubMed

Fleseriu M, Petersenn S (2012) Medical management of Cushing’s disease: what is the future? Pituitary 15(3):330–341. doi:10.1007/s11102-012-0397-5 CrossRefPubMedCentralPubMed

Cuevas-Ramos D, Fleseriu M (2014) Treatment of Cushing’s disease: a mechanistic update. J Endocrinol 223(2):R19–R39. doi:10.1530/joe-14-0300 CrossRefPubMed

Nieman LK (2013) Update in the medical therapy of Cushing’s disease. Curr Opin Endocrinol Diabetes Obes 20(4):330–334. doi:10.1097/MED.0b013e3283631809 PubMedCentralPubMed

Mete O, Asa SL (2013) Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol 30(3):158–164. doi:10.1053/j.semdp.2013.06.002 CrossRefPubMed

10.

Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol 22(4):443–453. doi:10.1111/j.1750-3639.2012.00599.x CrossRefPubMed

11.

Asa SL (2011) Tumors of the pituitary Gland, vol. Fascicle 15, 4th Series. The Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington, DC

12.

Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, Teramoto A (2008) Pathology of the human pituitary adenomas. Histochem Cell Biol 130(3):495–507. doi:10.1007/s00418-008-0472-1 CrossRefPubMedCentralPubMed

13.

Syro LV, Builes CE, Di Ieva A, Sav A, Rotondo F, Kovacs K (2014) Improving differential diagnosis of pituitary adenomas. Expert Rev Endocrinol Metab 9(4):377–386. doi:10.1586/17446651.2014.922412 CrossRef

14.

Cuevas-Ramos D, Fleseriu M (2014) Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 52(3):R223–R240. doi:10.1530/jme-14-0011 CrossRefPubMed

15.

Chinezu L, Vasiljevic A, Jouanneau E, Francois P, Borda A, Trouillas J, Raverot G (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45(1):71–77. doi:10.1016/j.humpath.2013.08.007 CrossRefPubMed

16.

Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49(2):R69–R78. doi:10.1530/jme-12-0113 CrossRefPubMed

17.

Sav A, Rotondo F, Syro LV, Scheithauer BW, Kovacs K (2012) Biomarkers of pituitary neoplasms. Anticancer Res 32(11):4639–4654PubMed

18.

Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S (2009) High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing’s disease. Eur J Endocrinol 161(4):553–559. doi:10.1530/EJE-09-0414 CrossRefPubMed

19.

Salehi F, Scheithauer BW, Kovacs K, Horvath E, Syro LV, Sharma S, Manoranjan B, Cusimano M (2012) O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery 70(2):491–496. doi:10.1227/NEU.0b013e318230ac63; discussion 496CrossRefPubMed

20.

McCormack A, Kaplan W, Gill AJ, Little N, Cook R, Robinson B, Clifton-Bligh R (2013) MGMT expression and pituitary tumours: relationship to tumour biology. Pituitary 16(2):208–219. doi:10.1007/s11102-012-0406-8 CrossRefPubMed

21.

Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thome C (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760–763. doi:10.1055/s-0030-1253419 CrossRefPubMed

22.

Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL (2011) Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary 14(4):418–424. doi:10.1007/s11102-009-0211-1 CrossRefPubMedCentralPubMed

23.

Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 74(4):E447–E455. doi:10.1227/neu.0000000000000251; discussion E455CrossRefPubMed

24.

Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. doi:10.1007/s00401-013-1084-y CrossRefPubMed

25.

Raverot G, Jouanneau E, Trouillas J (2014) Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol. doi:10.1530/eje-13-1031

26.

Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas–diagnosis and emerging treatments. Nat Rev Endocrinol 10(7):423–435. doi:10.1038/nrendo.2014.64 PubMed

27.

Crooke AC (1935) A change in the basophil cells of the pituitary gland common to conditions which exhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol 41:339–349CrossRef

28.

George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Meyer FB (2003) Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27(10):1330–1336CrossRefPubMed

29.

Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P (2001) Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12(3):329–341CrossRefPubMed

30.

Heaney AP (2011) Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96(12):3649–3660. doi:10.1210/jc.2011-2031 CrossRefPubMedCentralPubMed

31.

Thynne T, White GH, Burt MG (2014) Factitious Cushing’s syndrome masquerading as Cushing’s disease. Clin Endocrinol 80(3):328–332. doi:10.1111/cen.12343 CrossRef

32.

Romanholi DJ, Salgado LR (2007) Pseudo-Cushing states. Arquivos brasileiros de endocrinologia e metabologia 51(8):1303–1313CrossRefPubMed

33.

Shahani S, Nudelman R, Nalini R, Kim H-S, Samson S (2010) Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol 5(1):56CrossRefPubMedCentralPubMed

Title: Current status on histological classification in Cushing’s disease
Authors: Luis V. Syro
Fabio Rotondo
Michael D. Cusimano
Antonio Di Ieva
Eva Horvath
Lina M. Restrepo
Min Wong
Donald W. Killinger
Harley Smyth
Kalman Kovacs
Publication date: 01-04-2015
Publisher: Springer US
Published in: Pituitary / Issue 2/2015
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-014-0619-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2015

Cushing disease: Where do we stand, where are we heading?

A pitfall in diagnosing Cushing’s disease: ectopic ACTH-producing pituitary adenoma in the sphenoid sinus

Diagnosis of Cushing’s disease

Screening for Cushing’s syndrome: Is it worthwhile?

Medical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers

Surgical management of Cushing’s disease

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage